Cancer Immunology, Immunotherapy

, Volume 62, Issue 5, pp 949–954

CD40 immunotherapy for pancreatic cancer

  • Robert H. Vonderheide
  • David L. Bajor
  • Rafael Winograd
  • Rebecca A. Evans
  • Lauren J. Bayne
  • Gregory L. Beatty
Focussed Research Review

DOI: 10.1007/s00262-013-1427-5

Cite this article as:
Vonderheide, R.H., Bajor, D.L., Winograd, R. et al. Cancer Immunol Immunother (2013) 62: 949. doi:10.1007/s00262-013-1427-5

Abstract

Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive and lethal cancer which is poorly responsive to standard therapies. Although the PDA tumor microenvironment is considered especially immunosuppressive, recent data mostly from genetically engineered and other mouse models of the disease suggest that novel immunotherapeutic approaches hold promise. Here, we describe both laboratory and clinical efforts to target the CD40 pathway for immunotherapy in PDA. Findings suggest that CD40 agonists can mediate both T-cell-dependent and T-cell-independent immune mechanisms of tumor regression in mice and patients. T-cell-independent mechanisms are associated with macrophage activation and the destruction of PDA tumor stroma, supporting the concept that immune modulation of the tumor microenvironment represents a useful approach in cancer immunotherapy.

Keywords

Tumor immunity CD40 Pancreatic cancer Macrophages T cells CIMT 2012 

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Robert H. Vonderheide
    • 1
    • 2
  • David L. Bajor
    • 1
    • 2
  • Rafael Winograd
    • 1
  • Rebecca A. Evans
    • 1
  • Lauren J. Bayne
    • 1
  • Gregory L. Beatty
    • 2
  1. 1.Abramson Family Cancer Research Institute, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Division of Hematology-Oncology, Department of Medicine, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations